title: Suppression of experimental uveitis in rats by anti-I-A antibodies.
abstract: I-region-associated (Ia) class II major histocompatibility complex (MHC) products are known to play a major role in autoimmunity. Effects of anti-I-A and anti-I-E monoclonal antibodies on development of experimental autoimmune uveitis (EAU) were investigated in Lewis rats. Prior to sensitization with S-antigen, seven groups of rats, six in each group, were injected intraperitoneally with one of the following agents. Groups 1, 2, and 3 (controls) received saline, RPMI and mouse immunoglobulin G (IgG), respectively. Groups 4 and 5 were injected with anti-I-E antibodies, 80 micrograms and 1000 micrograms, respectively. Similarly, groups 6 and 7 received anti-I-A, 100 micrograms and 750 micrograms, respectively. The treatments were repeated on days 1, 2, 5, 8, and 11 after S-antigen injection. All these animals were killed on day 18. In addition, two groups of rats sensitized with S-antigen were treated with 750 micrograms anti-I-A antibodies on days 5, 6, and 7 (group 8) and on days 7, 8 and 9 (group 9). An additional group (group 10) of Lewis rats was treated with 750 micrograms anti-I-A 1 day prior to and on days 1 and 2 after S-antigen injection. These group-10 animals were killed on day 31. Histopathologically, the enucleated globes of animals treated with high dose anti-I-A revealed marked suppression or inhibition of uveitis development. Such inhibition was virtually complete when the antibody was administered within a week of S-antigen injection, and the inhibitory effect lasted for at least 31 days.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Doheny Eye Institute, Los Angeles, CA 90033.
authors.forename: N A
authors.initials: NA
authors.lastname: Rao
authors.forename: L
authors.initials: L
authors.lastname: Atalla
authors.forename: M
authors.initials: M
authors.lastname: Linker-Israeli
authors.forename: F Y
authors.initials: FY
authors.lastname: Chen
authors.forename: F W
authors.initials: FW
authors.lastname: George
authors.forename: W J
authors.initials: WJ
authors.lastname: Martin
authors.forename: L
authors.initials: L
authors.lastname: Steinman
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D000918:Antibody Specificity; D000941:Antigens / Q000276:immunology; D019393:Arrestin; D001323:Autoantibodies / Q000008:administration & dosage* / Q000276:immunology; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000276:immunology; D005434:Flow Cytometry; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D007124:Immunoenzyme Techniques; D007167:Immunotherapy; D008213:Lymphocyte Activation; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors; D014605:Uveitis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D000941:Antigens; D019393:Arrestin; D001323:Autoantibodies; D005136:Eye Proteins; D000949:Histocompatibility Antigens Class II